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ABSTRACT
G protein-coupled receptors (GPCRs) are integral cell-surface proteins having 
a central role in tumor growth and metastasis. However, several GPCRs retain an 
atypical intracellular/nuclear location in various types of cancer. The pathological 
significance of this is currently unknown. Here we extend this observation by showing 
that the bradykinin B2R (BK-B2R) is nuclearly expressed in the human triple-negative 
breast cancer (TNBC) cell line MDA-MB-231 and in human clinical specimens of TNBC. 
We posited that these “nuclearized” receptors could be involved in oncogenic signaling 
linked to aberrant growth and survival maintenance of TNBC. We used cell-penetrating 
BK-B2R antagonists, including FR173657 and novel transducible, cell-permeable forms 
of the peptide B2R antagonist HOE 140 (NG68, NG134) to demonstrate their superior 
efficacy over impermeable ones (HOE 140), in blocking proliferation and promoting 
apoptosis of MDA-MB-231 cells. Some showed an even greater antineoplastic 
activity over conventional chemotherapeutic drugs in vitro. The cell-permeable B2R 
antagonists had less to no anticancer effects on B2R shRNA-knockdown or non-B2R 
expressing (COS-1) cells, indicating specificity in their action. Possible mechanisms 
of their anticancer effects may involve activation of p38kinase/p27Kip1 pathways. 
Together, our data support the existence of a possible intracrine signaling pathway via 
internal/nuclear B2R, critical for the growth of TNBC cells, and identify new chemical 
entities that enable to target the corresponding intracellular GPCRs. 
INTRODUCTION
Breast cancer (BC) is the most frequently diagnosed 
cancer in North America and figures among the leading 
causes of cancer deaths in women worldwide [1]. This 
situation remains true despite improvements in screening 
and treatment. Non-invasive forms of BC most often 
originate from the galactophorous ducts and lobules 
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(the milk-producing glands) and are classified as ductal 
carcinoma in situ (DCIS) or lobular carcinoma in situ 
(LCIS). They are generally benign tumors accounting 
for approximately 20% and 1% of all newly diagnosed 
BC cases, respectively [2]. These tumors are highly 
curable if not very manageable cancers but they are seen 
as precursors of invasive BC. Invasive ductal carcinoma 
is the most common type of BC, representing 65 to 85% 
of all cases. Current treatment options and prognosis 
for invasive BC vary depending on various factors, 
including the histopathological type, grade, stage and 
steroid receptors (estrogen and progesterone receptors 
(ER and PR)) and epidermal growth factor receptor-2 
(HER2/neu) status. Currently available treatments include 
some combination of surgery, radiation, chemotherapy, 
hormonal therapy, and targeted therapies including the use 
of monoclonal antibodies (e.g. trastuzumab; Herceptin®) 
notably for HER-2-positive patients [3]. 
The triple-negative breast cancer (TNBC), defined 
by the absence of ER, PR and HER2 expression, 
accounts for 10–20% of newly diagnosed cases of 
invasive BC. TNBC encompasses a remarkably 
genetically heterogenous group of tumors with different 
clinicopathological features. It is associated with 
aggressive growth and increased risk of local recurrence 
and distant metastasis (brain and lung), and of developing 
high resistance to chemotherapy. For these reasons, it 
remains the hardest BC subtype to treat and prognosis is 
poor compared to all BC subtypes [4]. In fact, the overall 
5-year rate for patients with late-stage (metastatic) TNBC 
is less than 30%, despite chemotherapy, the mainstay of 
adjuvant treatment for this condition [3, 4]. The lack of 
effective treatments for TNBC warrants the identification 
of new molecular targets and approaches to develop 
efficient therapeutic agents for the treatment of TNBC.
G protein-coupled receptors (GPCRs) are integral 
cell-surface proteins having a central role in tumor 
growth, invasion and metastasis, angiogenesis and 
chemotherapy resistance [5, 6]. Among those implicated 
in BC progression, in particular, include thrombin-
PAR-1, PGE2-EP2/EP4, SDF1-CXCR4, oestrogen-
GPR30 and kinin B1/B2 receptors (B1R/B2R) [5, 7, 8]. 
Given their major contribution to tumor development and 
progression, they represent promising therapeutic targets 
for developing next-generation anticancer therapies [6]. 
However, many GPCRs retain an atypical intracellular/
nuclear location in various types of cancer, distinct from 
its classical location on plasma membrane [9, 10]. The 
pathological significance of this is currently unknown. 
Moreover, immunological profiling studies, performed 
on clinical biopsy specimens from cancer patients, 
suggested that the nuclear presence of some GPCRs (e.g., 
CXCR4 [11], CysLT1 [12], EMR-2 [13], EP1 receptor 
[14]), in analogy to nuclear receptor tyrosine kinases 
(e.g., EGFR [15, 16] and VEGFR1 [17]), might carry 
predictive and prognostic values in malignancies as in 
the case of breast, uterine and prostate cancers. Atypical 
pattern of increased intracellular/nuclear subdistribution 
encountered in some types of cancer may be functionally 
significant in the process of tumor growth. Indeed, there 
is compelling evidence suggesting that GPCRs can also 
function intracellularly on endoplasmic reticulum/nuclear 
membranes to promote noncanonical signaling in health 
and diseases such as cancer [9, 10, 18–20]. Such signaling 
mechanism of GPCRs, acting within intracellular space 
at subcellular organelles, is known as intracrine signaling 
[19]. Intracellular/nuclear GPCRs may be 1) constitutively 
active, 2) activated by internal, newly synthesized 
ligands avoiding secretory pathways, or 3) activated by 
internalized extracellular ligands through mechanisms 
dependent or not of receptor-mediated endocytosis and 
endosomal escape of ligands [10, 19, 21–23]. 
Kinins are a family of peptides which exert 
regulatory control over cellular processes important for 
tumor growth, survival, invasion, and angiogenesis of 
several kinds of cancers [7, 24]. In particular, BK, acting 
through the GPCR B2R, is implicated in neoplastic growth. 
In accordance, antagonism of B2R was shown to impair 
tumor cell proliferation, migration and invasiveness in 
some preclinical models of cancer [7, 24, 25]. However, 
these findings could apply to some but not all of the 
various B2R antagonists studied (e.g., active BKM570, 
B9870 vs non-active B9430) [24, 25]; an observation 
that could be attributed not only to differences in their 
pharmacological activities but also to specific particular 
physicochemical characteristics between these antagonists, 
which might affect their movement across cell membrane. 
Consistent with the notion that kinins may act in an 
autocrine/intracrine fashion to regulate gene expression 
is the presence of elevated nuclear B1R and B2R levels 
as well as the plasma (hKB1) and/or tissue (hK1) kinin 
forming enzyme kallikreins, that have been reported in 
certain types of human cancer, such as malignant pleural 
mesotheliomas [26], lung cancer [27], breast cancer [28] 
and high-grade [WHO grade IV] gliomas [9]. Results from 
our exploratory investigation showed that nuclear B2R are 
prominently expressed in the aggressive, TNBC cell line 
MDA-MB-231 and in TNBC clinical specimens (Figure 
1). Collectively, these findings have led us to believe that 
nuclearly-located B2R may have an important role to play 
in the overall functions of the receptors contributing to the 
growth of TNBC; accordingly, cell-penetrating selective 
B2R antagonists (CP-B2RAs) are critical to validate 
function and provide the required tools in developing 
drug prototypes. In the present study, we used novel cell-
permeable (transducible) forms of peptide as well as non-
peptidic B2R antagonists as pharmacological tools to 
explore internal/nuclear B2R activity in MDA-MB-231 
cells as a representative in vitro TNBC model [29]. Our 
findings show that a multi-compartment targeting approach 
(i.e. to plasma and nuclear membranes) by means of CP-
B2RAs can be used to enhance killing of tumor cells.
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RESULTS
Overexpression and nuclear localization of B2R 
in the agressive TNBC cell line MDA-MB-231 
and in clinical TNBC specimens 
We first sought to examine the expression and 
subcellular localization of B2R in MDA-MB-231 cells 
by FACS using the specific antisera AS276–83, which 
recognize both intracellular and extracellular domains 
of B2R [30]. These experiments were made under non-
permeabilized and permeabilized conditions for labeling 
cell-surface and intracellular B2R, respectively. B2R 
immunostaining was identified on the plasma membrane 
but was more abundant in intracellular compartments 
(Figure 1A). These results agree with those obtained 
by Morissette et al. who showed that MDA-MB-231 
Figure 1: Cellular/nuclear expression of B2R in the human TNBC cell line MDA-MB-231. (A) Immunostaining of B2R 
on unpermeabilized and permeabilized (saponin-treated) MDA-MB-231 cells and on isolated nuclei derived from these cells analyzed by 
FACS. Experiments were performed using two distinct anti-B2R antibodies: AS276–83 and LS-A797. The second antibody was Alexa 
Fluor 488® dye conjugated goat anti-rabbit antibody. One out of two representative experiments is shown. (B) Competitive binding of 
radiolabeled HOE140 (0.5 nM) with R954 (10 µM) and HOE140 (10 µM) on nuclei isolated from MDA-MB-231 cells. *p < 0.05 versus 
indicated group (unpaired Student’s t test). Inset. Micrograph depicting the purity ( > 90%) of the nuclear fractions. (C) Detection of B2R in 
purified fractions of plasma membrane (M) and nuclei (N) by western blotting. A repetition of the experiment gave similar results. Prepared 
nuclear fractions demonstrated lack of immunoreactivity with the organelle specific antibodies to Clathrin and Na+/K+ATPase (plasma 
membrane), LAMP-2 (lysosome) and GM130 (cis-Golgi), and high immunoreactivity with lamin A/C (nucleus) and calnexin (endoplasmic 
reticulum). Conversely, membrane microsomes exhibited high immunoreactivity against Clathrin, Na+/K+ATPase and GM130, and no 
immunoreactivity to lamin A/C, calnexin and LAMP-2. 
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cells displayed low cell-surface levels of B2R [31]. 
Interestingly, we found that nuclei isolated from MDA-
MB-231 cells similarly stained intensely (Figure 1A). 
The presence of specific BK receptor sites in purified 
nuclei isolated from MDA-MB-231 cells was confirmed 
by marking the B2R with a distinct anti-B2R primary 
antibody (LS-A797) (Figure 1A). The specificities of 
the two primary antibodies used were priorly established 
elsewhere [30, 32, 33] and further described herein by 
immunoblotting of transfected cells and by FACS analysis 
on tissues obtained from wild-type and knock-out mice 
(Supplementary Figure 1). Moreover, competition-binding 
studies on isolated MDA-MB-231 nuclei using [125I]-hpp-
HOE 140 (B2R antagonist) indicated binding sites with a 
pharmacological profile typical of B2R as the unlabeled 
B2RA HOE 140, but not the B1RA R-954, was able to 
displace the bound radioligand (Figure 1B).
To further substantiate the results reporting nuclear 
localization of B2R, we carried out western blot analysis 
on enriched cell membranous and nuclear fractions from 
MDA-MB-231 cells following proper validation of these 
organelle fractions (Figure 1C). We detected a specific anti-
B2R immunoreactive band in the nucleus closely matching 
those detected in plasma membranes, the latter of which 
appear as two protein doublets, representing possibly 
different glycosylated protein isoforms (Figure 1C) [33, 34]. 
These results demonstrate that the full-length B2R localised 
to nuclei and are competent to bind cognate ligands.
In an initial effort to translate the in vitro findings 
to human, we also examined the expression of B2R in 
few clinical BC specimens tested negative for ER, PR 
and HER2, and in adjacent normal tissue samples taken 
as controls. For this purpose, we used high-resolution 
immunogold electron microscopy to ascertain the in situ 
subcellular localization of B2R in these human tissues 
(Figure 2). We found overall higher B2R immunogold 
labeling in TNBC specimens compared to matched-
normal breast tissues. As expected, the presence of B2R 
was visualized at the cell surface and intracellularly 
(presumably in vesicles) in TNBC cells (Figure 2). The 
number of gold particles detected at the plasma membrane 
components of normal and TNBC tissues were judged too 
small and inconsistent to find important differences as 
significant.
Most interestingly, we also detected B2R at 
extracellular vesicles, also refered to as shedding 
microvesicles or exosomes, pointing out to expanded roles 
for B2R in TNBC. It is believed that these tumor-derived 
exosomes can accelerate cancer progression and metastasis 
by allowing intercellular transfer of membrane and soluble 
proteins and microARNs in microenvironmental recipient 
cells [35]. 
Figure 2: Overexpression and nuclear localization of B2R in clinical TNBC specimens. Detection of B2R in TNBC and 
normal adjacent breast tissue biopsies was assessed using transmission electron microscopy. Positive immunogold B2R labeling at the cell 
nucleus (N) and nuclear envelopes (NE), cytoplasm (Cyt), plasma membrane (PM) and on extracellular vesicles (EV) (arrow heads). No 
staining was observed using the isotype control antibody. Representative electron micrographs of human normal breast and TNBC samples 
stained with a specific antiserum against B2R are shown. Histographic representation of B2R quantification in electron microscopic 
micrographs showing high receptor density in TNBC, at both cytoplasmic and nuclear compartments, compared to normal tissue samples 
adjacent to tumors. ***p < 0.001 versus normal tissues, as determined with Student’s t-tests.
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Quantitatively, marked differences appeared in the 
nuclear and cytoplasmic distribution of B2R between 
normal and TNBC tissues (Figure 2); B2R density 
being about 3-fold higher in TNBC than normal at both 
compartments. These EM data also confirmed the striking 
variation in the subcellular patterns of expression of B2R 
in normal and TNBC. Collectively, these results raise the 
possibility that an intracellular/nuclear pool of B2R may 
exist and be biologically relevant for TNBC growth. 
Assessment of pharmacological and cell-
penetrating properties of B2RAs
It is recognized that hydrophilic, polar peptide 
molecules, like BK, do not readily cross cell membrane on 
their own. Different strategies can however be employed 
to facilitate their cellular entry into living cells/tissues 
and ensuing binding to cognate receptors residing inside 
the cells. Among these, peptide linkage or conjugation 
with non-immunogenic, non-toxic transduction vectors, 
consisting of lipids, oligosaccharides and cationic 
peptides, such as the well-known HIV-1 Tat peptide (48–
58 sequence) has been found useful [36–38]. To address 
putative functions of intracellular B2R, we took into 
account some of these strategies and designed two dTat-
based kinin peptide analogs of BK and HOE 140 (Table 1). 
To increase the lipophilicity and transcellular permeability 
of HOE 140, we also designed a novel delivery vector 
composed of steroidal cholic acid, having no known 
ability to activate soluble steroid/nuclear receptors and/or 
GPCRs recognized by lipid mediators [39]. Our data from 
radioligand binding assays (on adherent HEK-293T cells 
transfected with B2R) and functional studies (isometric 
contraction of human vessels) revealed that covalent 
conjugation of B2RA HOE 140 with the selected carrier 
vectors did not influence its binding and activity at the 
cellular level (Table 1). Only dTat-BK showed reductions 
in both binding affinity (110 ± 4 nM vs 4.9 ± 0.6 nM) and 
biological activity (350 ± 1 nM vs 3.0 ± 0.4 nM) compared 
to BK in vitro. Direct measument of intracellular contents 
of the B2RAs by LC-MS/MS were made after different 
incubation periods with MDA-MB-231 cells to determine 
their permeability characteristics (Table 1). These assays 
were complemented by additional measures of their 
corresponding log D7.4 values. Our results showed that the 
non-peptide B2RA FR173657, as well as the lipopeptide 
B2RA Cholic-HOE 140 (NG134), can translocate across 
the plasma membrane into the cell cytoplasm, albeit 
with quite different uptake rates (Table 1). These are 
in accordance with the high distribution coefficients 
measured for these latter antagonists (log D7.4 > 0), 
supporting their passive transport across cell membranes 
(Table 1). As anticipated, the dTat-HOE 140 conjugate 
(NG68) also accumulated over time within MDA-MB-231 
cells as opposed to its unconjugated parent peptide HOE 
140 (Table 1).
Using confocal microscopy, we further demonstrated 
the ability of fluorescent dTat-HOE 140 conjugate 
(NG68) to readily gain access to intracellular sites then 
progressively to nuclear compartments of MDA-MB-231 
cancer cells whereas the unconjugated HOE 140 can only 
bind to cell surface receptors (Figure 3A). These results 
closely resembled those obtained by immunofluorescence, 
under nonpermeabilized or permeabilized conditions, 
showing the small fine-punctate appearance of B2R 
immunoreactivity along the cell surface of MDA-
MB-231 cells, while the strongest staining being observed 
intracellularly at the perinuclear and nucleolar regions 
(Figure 3B).
CP-B2RAs impaired clonogenic / proliferative 
potential of MDA-MB-231 cells
With these new tools at hand, we then proceeded 
in comparing the effects of membrane permeant and non 
permeant B2R ligands on cell proliferation/growth of 
TNBC cells using clonogenic assays. Colony number and 
surface area were both used as clonogenic assay endpoints 
to evaluate the effects of agonists (Figure 4A). Incubation 
of MDA-MB-231 cells with the biologically active, 
transducible B2R agonist dTat-BK did not increase colony 
number, but resulted in an increase in colony surface 
area, with a forming bell-shaped concentration-response 
curve. The causes behind such hormetic effect are unclear. 
Comparatively, the unmodified parent peptide agonist BK 
was ineffective. In addition, we found that only the cell 
permeable B2R antagonists, NG68, NG134 and FR173657 
showed concentration-responsive clonal repression. 
HOE140 (up to 100 μM) did not prevent colony formation 
(Figure 4B), even when added on a daily basis for a period 
of 10 days (not shown). Similar results were found using 
other human B2R-expressing carcinoma cell lines, such 
as U87-MG glioblastoma and A549 lung cancer cells 
(Supplementary Figure 2). Furthermore, blocking cell-
surface B2R with a saturating concentration of HOE140 
(10 μM) prior to treatment with the CP-B2RAs did not 
affect their inhibitory activity against cell proliferation 
(Figure 4C). 
In another set of experiments, we studied the 
possible competition for intracellular receptor binding 
sites between the B2R agonist and antagonist. For this, 
we used the non-permeable peptide antagonist HOE 
140 (in excess) to selectively block cell-surface B2R in 
MDA-MD-231 cells while exposing intracellular/nuclear 
B2R with the membrane pemeant agonist dTat-BK, with 
or without CP-B2RAs (Figure 4C). Results showed that 
the addition of dTat-BK to the extracellular medium does 
partly rescue cells from inhibition of proliferation induced 
by FR173657 or NG68. This would suggest a possible 
competition for receptor binding between these two 
agents at intracellular locations, most likely the nucleus. 
Similar anti-proliferative effects of CP-B2RAs (at 10 
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Figure 3: Binding and cellular incorporation of B2RAs in MDA-MB-231 cells. (A) MDA-MB-231 cells were incubated with 
FITC-labelled peptide HOE140 or NG68 (10 µM) at 37°C for the indicated times, washed with PBS buffer, fixed with paraformaldehyde 
then analyzed by laser confocal microscopy. A pseudocolor fluorescence intensity scale is shown on the right; black being the lowest and 
white the highest value. Note the rapid cellular incorporation of FITC-NG68 peptide and its perinuclear/nucleolar localization increasing 
over time while FITC-HOE140 conserved an exclusive membrane distribution. No signal was detected when cells were incubated with 
FITC alone under the same experimental conditions. Individual midsection confocal images are representative of three replicates. (B) 
Immunocytochemical localization of B2R in MDA-MB-231 cells was performed in unpermeabilized (upper panels) and permeabilized 
(bottom panels) conditions using the B2R antiserum AS276–83. An Alexa Fluor 568-conjugated goat anti-rabbit IgG antibody was used 
as a secondary antibody. Nuclei stained with Hoescht 33342 (middle panels, arbitrary colors). Merge in right panels. Negative control: no 
primary antibody. Pseudocolor fluorescence intensity scale as in A. Representative confocal middle z-sections are shown.
Table 1: Human kinin B2R binding and pharmacological activities, distribution coefficient and 
cell permeability values of agents used in the study
Agents / Code name Binding
hB2R-HEK293T
IC50 (nM)
Bioassay
hUV
IC50 (nM)
Distribution 
coefficient 
log D, n-octanol/
PBS (pH 7.4)
Cellular incorporation 
(pmol/106 cells)
15 min 4 h 24 h 
HOE 140 5.3 ± 1.7* 3.8 ± 0.3* -3.06 0 0 0
FR 173657 37.0 ± 1.6* 6.0 ± 0.8* 2.89 116 139 185
d-Tat-HOE 140 (NG68) 5.2 ± 1.0 18.0 ± 4.0 -3.02 5 14 21
Cholic-HOE 140 (NG134) 19.0 ± 6.5 6.5 ± 2.5  0.21 13 22 63
Values are means ± s.e.m. *Data taken from ref. [34]. Binding assays were performed using living adherent HEK-293T 
cells transiently transfected with hB2R. Pharmacological activities of B2RAs were performed on human de-endothelized 
umbilical veins (hUV). Distribution coefficient of compounds between n-octanol and 0.1 M sodium phosphate buffer, pH 
7.4, was determined by the shake flask methodology. Compound content of the aqueous and octanol phases was quantified 
by RP-HPLC. Cellular incorporation of B2RAs within MDA-MB-231 cells were assessed using a tandem quadrupole LC-
MS/MS system. Results are the average of two independent assays. 
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µM), but not of HOE 140, were observed in anchorage-
independent growth (Figure 4D) and common MTT assays 
(Figure 5), adding further support for an inhibitory effect 
of CP-B2RAs on TNBC growth. As it was observed in 
clonogenic assays (Figure 4A), the addition of BK alone 
at high concentration (10 µM) to MDA-MD-231 cells did 
not induce cell proliferation according to metabolic MTT 
assays (data not shown).
CP-B2RAs induced apoptotic death and cell 
cycle arrest of MDA-MB-231 cells
Beside the inhibition of proliferation and 
clonogenicity, we evaluated whether the two most potent 
CP-B2RAs, FR173657 and NG68, may also disrupt other 
cancer processes as maintenance of cell viability (through 
activation of either apoptosis or senescence program) 
Figure 4: CP-B2RAs abrogate clonogenic potential of MDA-MB-231 cells. (A) Effects of B2R agonists on colony size and 
numbers determined by anchorage-dependent clonogenic assays. Cells were incubated in the presence or absence of indicated concentrations 
of agonists and colonies allowed to form over a 10–14 day period. (B) Effects of B2RAs on colony numbers. Experiments performed as 
described in A. DMSO vehicle control (0.2%), serving the maximal concentration tested of FR173657 (25 µM), did not have any marked 
effects on clonogenicity (not shown). (C) Growth competition assays with CP-B2R agonist dTat-BK and CP-B2RAs, NG68 and FR173657. 
Cells were first incubated with a saturating concentration of HOE 140 (to selectively block cell-surface B2R) then treated with the dTat-
BK, with or without CP-B2RAs, at the indicated concentrations. Representative photographs of stained colonies following the indicated 
treatments are shown above graph. (D) Effects of B2RAs on cell growth assessed by anchorage-independent (in soft agar) clonogenic 
assays. Cells were exposed to the indicated concentrations of compounds for 7 days. Colony formation in soft agar was assayed as described 
in Materials and Methods. For panels A-D, data represent means ± s.e.m. of 4–8 experiments. *p < 0.05, **p < 0.01, ***p < 0.001 versus Ctl 
(Dunnett’s test); ††p < 0.01 versus indicated group (unpaired Student’s t test).
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and cell cycle progression (Figure 6). We demonstrated 
that MDA-MB-231 cells underwent apoptosis, but 
not senescence, as a result of CP-B2RA treatments, 
as evidenced by the Annexin V and active caspase-3 
positivity (Figure 6A) and the lack of expression of 
β-galactosidase, a widely used senescence biomarker 
(Figure 6B). In contrast, B2R non-expressing COS-1 
cells were only minimally affected when exposed to high 
concentrations of CP-B2RAs (Figure 6A), indicating a 
good degree of specificity of these antagonists for B2R 
target. Control experiments showed that vector dTat alone 
did not exhibit intrinsic activity (up to 100 μM) in any 
of the above assays, as expected from literature precedent 
[40]. We also found that both FR173657 and NG68 tend 
to induce G0/G1 cell cycle arrest (Figure 6C), which 
could be one of the primary mechanism for the observed 
antiproliferative effects of these compounds. In contrast, 
HOE 140 (up to 100 μM) had no influence on cell cycle 
distribution of MDA-MB-231 cells (Figure 6C). Western 
analysis of selected proteins revealed that the CP-B2RAs 
NG68 and FR173657 may exert antiproliferative and 
apoptosis-inducing activities through both negative and 
positive regulatory effects of important proteins involved 
in different aspects of apoptosis and the cell cycle (Figure 
6D). For instance, both CP-B2RAs decreased the levels of 
MAPK and cyclin A, equally known to be overexpressed 
and causally implicated in the hyperproliferation of BC 
[41, 42]. FR173657 also appeared to reduce the levels of 
the anti-apoptotic protein XIAP. On the other hand, both 
CP-B2RAs increased expression of pro-apoptotic BAD 
and of the potent cell cycle inhibitor p27Kip1 in MDA-
MB-231 cells (Figure 6D). While the exact nature of 
these changes in protein expression remains to be fully 
understood, they stand compatible with a clear anticancer 
effect of the CP-B2RAs.
P38 MAPK signaling pathways contribute to the 
antigrowth activities of CP-B2RAs
It was shown that p38 MAPK, in particular p38α, 
can act as a tumor suppressor by inducing G1 cell-cycle 
arrest and apoptosis [43]. We therefore focused our 
attention on the p38-signaling pathway cascade and tested 
whether it is involved in the antiproliferative and pro-
apoptotic activities of CP-B2RAs (Figure 7). Results of 
western blot assays showed that the both FR173657 and 
Figure 5: Concentration-dependent anti-proliferative effects of CP-B2RAs on MDA-MB-231 cells. Cell proliferation 
assay was determined with colorimetric MTT as described under Materials and Methods. Data are means ± s.e.m. of optical density values 
from 5 to 8 experiments. *p < 0.05, **p < 0.01, ***p < 0.001 versus control (untreated) group at corresponding time point, using unpaired 
Student’s t test. 
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Figure 6: CP-B2RAs induce apoptotic death and cell cycle arrest of MDA-MB-231 cells. (A) Effects of B2RAs on apoptosis 
induction were investigated by Annexin V-FITC/ propidium iodide (PI) double staining followed by flow cytometry. Confluent cells 
were treated with the B2RAs at the indicated concentrations for 24h. Each bar represents mean values acquired from two independent 
experiments. (B) Effects of B2RAs on cellular senescence were analyzed by β-galactosidase staining following a 72h treatment. The pictures 
show representative contrast phase images of senescence-associated β-galactosidase expressing cells at 10x magnification. Serum-starved 
porcine cerebral microvascular endothelial cells (pCMVEC) served as a positive control for senescence. A repetition of the experiment 
gave similar results. (C) Effects of B2RAs on cell cycle were evaluated by flow cytometry of cells stained with PI. Each bar represents 
mean values acquired from two independent experiments. (D) Changed expression levels of cell cycle and apoptosis related proteins were 
evaluated after a 24h-treatment with B2RAs using Western blot analysis. Whole-cell lysates were blotted for the indicated proteins with the 
appropriate antibodies. Representative western blot of two independent experiments performed.  
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NG68, significantly increased the phosphorylation (and 
resultant activity) of p38 over time (Figure 7A). Moreover, 
pretreatment of MDA-MB-231 cells with the p38 MAPK 
inhibitor SB203580 (10 µM) attenuated the CP-B2RA-
induced increases of p27/Kip1 protein levels (Figure 7B) 
as well as their anti-proliferative activities in clonogenic 
assays (Figure 7C). 
shRNA-knockdown of B2R suppressed basal 
growth and antiproliferative activities of CP-
B2RAs in vitro
To determine whether B2R participated in the 
proliferative and clonogenic capacities of MDA-MB-231, 
and to further prove that the anticancer effects of CP-
B2RAs were not biased by unsuspected off-target effects, 
MDA-MB-231 cells were stably transduced with lentivirus 
expressing encoding either scrambled control sequence or 
shRNA targeting B2R (Figure 8). Knockdown efficiency of 
B2R was determined by qPCR and Western blot analyses. 
We found that both B2R mRNA and protein levels were 
reduced by up to 75–80% in the B2R-silenced MDA-
MB-231 cells compared to scrambled control shRNA-
treated cells (Figure 8A, 8B). Notably, depletion of B2R 
proteins was observed to the same extent at both nuclear 
and plasma membrane compartments as detected by 
Western blot (Figure 8B). Having validated the shRNA-
mediated gene silencing of B2R, we next investigated 
Figure 7: CP-B2RAs promote increased levels of the cell-cycle inhibitor p27kip and reduce clonogenic growth through 
p-38-dependent pathways. Effects of NG68 and FR173657 on (A) the phosphorylation (and activity) status of MAPK p38, and (B) 
the expression of p27kip1. To detect the phosphorylation of p38, cells were treated with or without CP-B2RAs for the indicated times. 
To determine p27 expression, cells were treated with the same antagonists at indicated concentrations for 24h. Whole cell lysates were 
analyzed by western blotting using the indicated antibodies. β-actin was used as an internal loading control in each case. Representative 
autoradiograms of 2–3 experiments. Also added in panel B are the effects of the MAPK p38 inhibitor SB203580 (SB) on FR173657 and 
NG68-triggered expressions of p27kip1. Cells pretreated for 6h with SB (10 µM) were treated with CP-B2RAs at indicated concentrations 
for 24h. Whole cell lysates were prepared and analyzed by Western blot as in A. (C) Effects of MAPK p38 inhibitor, SB203580 on 
FR173657- and NG68-induced anti-clonogenic activities against MDA-MB-231 cells. Cells pretreated for 6h with SB (10 µM) were treated 
with or without CP-B2RAs at indicated concentrations for 14 days. Clonogenecity efficiency was evaluated as described in Figure  3; SB 
alone had no effect (not shown). Data are as mean ± s.e.m. of 6–8 experiments. Ctl, control (no treatment). *p < 0.05 versus the indicated 
group, using Student’s t-test for unpaired samples. 
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Figure 8: Stable B2R knockdown affects basal growth and cytocidal activity of CP-B2RAs in MDA-MB-231 cells. 
(A–B) Knockdown efficiency of B2R was assessed using quantitative real-time PCR and western blot analyses. (A) Graph indicates the 
mean ± s.e.m. from 3 independent experiments. (B) The autoradiograms shown are representative of two experiments. (C–D) Effects 
of B2R depletion on clonogenic and proliferative potential of MDA-MB-231 cells under basal conditions. Clonogenicity and MTT cell 
proliferation experiments performed as described in Figures 3 and 4, and under Materials. (C) Graph indicates the mean ± s.e.m. from 3 
independent experiments. Representative images of methylene blue-stained colonies of MDA-MB-231 cells expressing B2R shRNA or a 
scrambled shRNA are shown on the right side. (D) Data are as mean ± s.e.m. of 6–8 experiments. (E) Altered expression of the proliferation 
marker Ki67 in MDA-MB-231 B2R knockdown cells measured by FACS. Data are representative of two independent experiments. (F) 
Effects of B2R depletion on the cytostatic activities of CP-B2RAs against MDA-MB-231 cells determined by MTT assays. Data are as 
mean ± s.e.m. of 6–8 experiments. Basal viability of ScrRNA was comparable to that of shRNA-1 (not shown). All statistical analyses were 
performed using Student’s t-test for unpaired samples. *p <  0.05, ***p < 0.001 versus the indicated group or corresponding time points.
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the effect of B2R knockdown on cell proliferation using 
clonogenic and MTT assays along with immunostaining 
of the proliferation marker protein Ki67 estimated by 
FACS (Figure 8C, 8D, 8E). We noted a marked, profound 
inhibition of proliferation and clonal growth (by more 
than 50%) of TNBC cells that had been depleted of B2R 
(Figure 8C, 8D). B2R knockdown MDA-MB-231 cells 
also demonstrated decreased levels of Ki67, confirming 
the intrinsic proliferation defect in these cells (Figure 8E). 
These results clearly indicate the involvement of B2R in 
the regulation of TNBC growth under basal (unstimulated) 
state. 
Importantly, B2R downregulation in MDA-MB-231 
cells significantly attenuated the cytostatic activities of 
both CP-B2RAs, FR173657 and NG68 (Figure 8F). These 
results and other also presented herein are congruent with 
the possibility that CP-B2RAs exert their anticancer action 
at least partly via intracellular-specific functional B2R, 
most likely located at the nucleus. 
Comparison of in vitro cytotoxic activities of CP-
B2RAs with standard chemotherapeutic agents 
currently in use for the treatment of TNBC
To highlight the importance of intracellular B2R 
in TNBC, we compared the relative effectiveness of 
CP-B2RAs with that of standard chemotherapies in 
inducing TNBC cell death by using MTT viability assays 
(Table 2). Chemotherapeutic drugs (e.g., BCNU, 
doxorubicin, carboplatin, temozolomide and paclitaxel) 
approved by the FDA for the treatment of TNBC were 
included in this analysis [3]. Anticancer potencies 
(expressed as mean IC50 values (µM)) of all tested agents 
are summarized in Table 2. Both CP-B2RAs, FR173657 
and NG68, showed strong anticancer potencies which were 
however slightly inferior (i.e. higher IC50 values) to those 
of doxorubicin and paclitaxel. On the other hand, both CP-
B2RAs were considerably more potent than the three DNA 
alkylating agents BCNU, carboplatin, and temozolomide. 
In fact, carboplatin and temozolomide did not show 
significant cytotoxic effect even at a concentration of 100 
µM. Lack of cytocidal activity of alkylating agents may 
not come as a surprise as MDA-MB-231 cells show the 
highest level of resistance to an array of chemotherapeutic 
drugs by comparison to other BC cancer lines (e.g. MDA-
MB-435, MDA-MB-468, MDA-MB-453S, and MCF-7), 
which is most likely due to MDR and P-gp overexpression 
and function [44].
To assess whether a combination of a CP-
B2RA with a chemotherapeutic agent may provide 
a mutual enhancement of the therapeutic effects, 
pair-wise combinations of these drugs (through IC25 
values) were analyzed in MDA-MB-231 cells, and cell 
viability inhibition was assessed as described earlier. 
The CalcuSyn program was then used to calculate 
combination indices (CI) for the two anticancer drugs. We 
found that the FR173657 and doxorubicin or paclitaxel 
combinations resulted in augmented killing of TNBC 
cells in a synergistic manner, as reflected by CI values 
well below 1. TNBC cell death was also augmented by 
NG68/paclitaxel or NG68/doxorubicin combinations, 
being additive (CI close to 1) to moderately synergistic 
(CI <  1), respectively. Thus, these results suggest that 
the combination of CP-B2RA and chemotherapeutic 
agents may provide a convenient means to optimize 
treatment of TNBC.
DISCUSSION
To elucidate the involvement of internal/nuclear 
GPCR, more specifically B2R, in TNBC tumorogenesis, 
we designed and/or characterized newly kinin CP-
B2RAs that were tested as anticancer agents. Here we 
present novel data demonstrating 1) strong constitutive 
intracellular/nuclear B2R localization in TNBC cells and 
tissue specimens; 2) that CP-B2RAs can interact with 
nuclear B2R sites and exhibit potent anticancer activities 
in cultured TNBC cells; a common mechanism underlying 
their anticancer effects may involve induction of G1-
phase growth arrest and apoptosis through activation 
of p38kinase/p27Kip1 pathways; and 3) that targeting 
intracellular B2R using CP-B2RAs is more effective 
than currently utilized chemotherapy (e.g., carboplatin, 
temozolomide) while acting synergistically or additively 
with others (e.g., doxorubicin or paclitaxel) to enhance 
their mutual cytocidal effects against TNBC cells.
The exact mechanism explaining the strong nuclear 
localization of B2R in TNBC cells/tissues remains unclear. 
Previous work by Lee et al. has led to the identification of 
a putative nuclear localization signal (NLS; motif K-K/R-
X-K/R) at the C-terminus of human B2R [45], which could 
contribute to explain the latter observation. In keeping 
with this strong possibility, several studies using deletion/
truncation NLS mutagenesis experiments have demonstrated 
the importance of an intact NLS for the nuclear localization 
or translocation and physiologic functions of several GPCRs, 
including the leukotriene CysLT1 receptor [12], angiotensin 
AT1 receptor [46], parathyroid hormone type 1 receptor 
[47], gonadotropin releasing hormone type 1 receptor [48], 
chemokine receptor CXCR4 [18], orphan receptor GPR158 
[49], formyl-peptide receptor 2 [50] and the platelet-
activating factor receptor [51]. Therefore, it is most likely 
that the nuclear import of B2R in TNBC cells occurs along 
this redundant pathway. We do not however rule out the 
contribution of other recently described alternate pathways 
involving small GTPases and sorting nexin proteins [23]. Our 
new findings, which describe the aberrant nuclear localization 
of B2R (via whatever mechanism) in TNBC are consistent 
with the recent work of Takano et al. demonstrating that B2R 
is able to form heterodimers with lamin C in the cell nucleus 
independent of BK stimulation [52].
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It should be noted that, although our data showed 
high nuclear localization of B2R and antineoplastic 
activities of the CP-B2RAs in MDA-MB-231 cells, these 
two phenomena may not be directly or strictly linked. 
Interaction of CP-B2RAs at subcellular sites other than the 
nuclear compartment may possibly exist for the CP-B2R 
to initiate intracellular signaling pathways contributing 
to their antiproliferative and cytocidal activities. Such 
inference is supported by many studies, though not related 
to the field of BC, describing the presence of functional 
native GPCRs at various organelles, such as mitochondria 
(e.g., angiotensin AT1R, cannabinoid CB1R), endosomes 
(e.g., adrenergic β2R, BK-B2R), lysosomes (e.g., 
cannabinoid CB1R, ocular albinism OA1R or GPR143), 
endolysosomes (e.g., L-α-lysophosphatidylinositol 
GPR55) and the endoplasmic reticulum (e.g., estrogen 
GPR30, vasopressin V2R) [53–56]. Other studies will be 
required to address this possibility. 
We, our collaborators and other colleagues, have 
demonstrated the existence and function of several 
GPCRs (e.g., PGE2/EP3, PAFR, LPA1R, AT1R, B2R, 
ApelinR, GnRHR, and trypsin/PAR2) along with their 
signal transducing components (e.g., Akt, MAPK p42/
p44, eNOS, and COX-2) at the cell nucleus of multiple 
cell types (see reviews [10, 19, 23, 57, 58]). These work 
has revealed new roles for these GPCRs in regulating 
nucleoplasmic calcium and ensuing expression of diverse 
target genes that are involved in inflammation and cell 
proliferation/growth [10, 19, 23, 33, 57, 59]. Importantly, 
these nuclear GPCRs can function in ways distinct from 
its plasma membrane counterpart. So far, however, 
most evidence to ascribe unequivocally the functional 
significance of nuclear GPCRs for peptides were obtained 
using in organello nuclear assays on intact nuclei isolated 
from cells and tissues under normal and pathological 
conditions (see reviews [10, 60]). Despite their obvious 
and substantial utility for introducing this new concept, 
there remains a definite need to validate the functions of 
nuclear GPCRs in living cells or organisms, and perharps 
even more so, in cancer pathology in which mitogenic 
signals may arise from persistent and excessive activity 
of nuclearly overexpressed GPCRs. With this in mind, 
we created novel molecule internalizing-vectors that can 
promote the permeation and incorporation of hydrophilic 
drugs as the potent peptide B2RA HOE 140 (Table 1), 
thus providing prototypic strategies to target intracellular/
nuclear GPCRs. Our results showed that our conjugation 
approach has succeeded in fulfilling the task and revealed 
that stabilized dTat is more effective than steroidal vector 
at delivering HOE 140 across the plasma membrane of 
MDA-MB-231 cells. Our results also established for the 
first time, to our knowledge, the cell-penetrating property 
of the non-peptide B2RA FR173657. Moreover, all of 
the newly-described CP-B2RAs turned out to be potent 
repressor of TNBC growth, mostly dependent of p38 
MAPK signaling. FR173657 was particularly effective in 
this regard. Its relative tendency to accumulate at much 
higher concentration than the other CP-B2RAs into tumor 
cells may explain the greater anticancer potency of the 
drug (Table 1). Such differences in the magnitude and 
rate of uptake between CP-B2RAs may reflect divergent 
paths of cellular entry and/or degradation after entering the 
cells. For instances, cellular uptake of lipophilic agent, as 
FR173657, can occur via passive membrane penetration 
while that of cationic Tat-peptides, as NG68, is believed 
to take place mostly by macropinocytosis [42].
Supplementary data on additional signal 
transduction pathways associated with the anticancer 
effects of FR173657 on MDA-MB-231 cells, determined 
through microarray gene-profiling studies, can be found 
online (see Table S1). It is conceivable that the important 
antitumor effects of FR173657 will be shared by other 
structurally-related, lipophilic non-peptide B2RAs, for 
example, the compound MEN16132 [61] or JSM10292 
[62]. Yet consistent with the idea of a possible intracrine 
action of B2RAs, is the strong and complex cytotoxic 
Table 2: Cytocidal activities of B2RAs and standard chemotherapeutic agents against MDA-
MB-231 cells
Agents IC50 values 
HOE 140 > 100 μM
FR173657 20 ± 1 μM
NG68 45 ± 1 μM
NG134 > 100 μM
BCNU (carmustine) 62 ± 1 μM 
Adriamycin (doxorubicin) 2 ± 1 μM
Carboplatin > 100 μM
Temozolomide (Temodar) > 100 μM
Paclitaxel (Taxol) 10 ± 1 μM
Data represent means ± s.e.m. (n = 6 to 8 experiments). Cell viability was established by the MTT assay after 72h drug 
exposure. IC50 values were calculated from complete concentration response-curve from no response to 80–100% cell death.
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effects reported with the small non peptide B2RA mimetic 
BKM570 on various human cancer cell lines, which 
are apparently mediated independently of cell-surface 
B2R functions [63, 64]. Furthermore, previous studies 
showed that the peptide B2RA B-9870 (CU201) can 
inhibit growth of breast tumor cells [31, 65], within the 
same concentration range of the CP-B2RAs used herein. 
Likewise NG68, B-9870 is an Arg-rich cationic peptide 
containing four Arg and two d-Arg. It is therefore possible 
that B-9870 can harbor the same effective cell membrane 
transduction property as that of NG68, allowing it to 
cross plasma membrane to reach intracellular space and 
intended target, as initially postulated by Morissette et al. 
[31]. It is interesting to note that, in our study, HOE 140 
was found inactive (up to 100 µM) as an anticancer drug 
while other in vitro studies have demonstrated that it can 
act as a potent mitogenic agonist [66] or, conversely, as 
a antiproliferative and apoptotic agents [67], albeit using 
cancer cell lines of other origins. 
Although alternative interpretations remain possible, 
the fact that the CPB2RAs still remained fully active even 
after having previously blocked cell-surface B2R with 
excess of HOE140 (10 µM) (Figure 4) and had reduced 
cytostatic activities in partly B2R depleted-TNBC cells 
(Figure 8), are highly suggestive signs of an intracrine 
mechanism at work. 
The mechanisms by which BK induces BC cell 
proliferation following activation of cell-surface B2R 
are not completely defined but may at least involve 
activation of the classical ERK/MAPK pathway [7, 25]. 
Recent seminal work by the group of Ehrenfeld et al. has 
shown that the kinin-generating kallikrein KLK1 and its 
substrates, kininogens, are expressed in estrogen-sensitive 
(MCF-7, T47D, ZR-75–1) and estrogen-insensitive 
(MDA-MB-231) BC cells [68]. In the present study, we 
managed to independently reproduce these results by 
immunolabeling and confocal microscopy (Supplementary 
Figure 3). We indeed detected the presence of endogenous 
kininogens-, kallikreins- and BK-like immunoreactivities 
in MDA-MB-231 cells not only in the cytoplasmic region, 
but also in the intranuclear region of MDA-MB-231 
cells (Supplementary Figure 3), which were generally 
characterized by a fine granular speckled cytoplasmic 
and nuclear staining. Such kinin-generating system was 
also reported to be present in the human glioblastoma cell 
line U-373 [69]. Overall, these results give credence to 
the possibility that the tumor-derived BK may be active 
both intracellularly (at nuclear sites) and extracellularly 
(upon its release) on cancer and stromal cells, thereby 
contributing to tumor growth and progression. The 
same tenet has also been postulated in the regulation of 
alternative functions of VPAC1 receptors depending on 
their spatial distribution in the development of breast 
cancers [20]. Future research is needed to shed more light 
on the biochemical mechanisms involved in the regulation 
of BK formation and circumscribed release either inside or 
outside cancer cells, allowing BK to operate via intracrine, 
autocrine or paracrine mechanisms. 
Several strategies have been used recently for 
dissecting membrane and nuclear effects of peptide 
hormones interacting with GPCRs in intact living cells. 
Among others, there are the use of cell permeabilization 
by pore-forming toxins or detergents and ligand 
intracellular microinjection [70–72]. While, there may 
be some concerns as to whether semi-intact cells reflect 
a genuine and valid model for intact living cells, both 
techniques may result in significant impediments to 
membrane integrity and cytoskeletal structure, leading to 
perturbation of cell functions [73, 74]. A new interesting 
approach has recently been developed to selectively 
study the intracrine signaling of peptide ligands (e.g., 
angiotensin and endothelin) via intracellular/nuclear 
GPCR, which consists of cell-permeant, photorelasable, 
caged ligands [75, 76]. The general principle is that, once 
the functionaly inert, caged ligand gets inside the cell, the 
ligand is released from the cage by exposing cells to UV 
lights, allowing it to interact and modulate functions of 
its cognate intracellular receptors. However, application of 
this approach in vivo, most notably in the context of cancer 
therapy (excluding skin cancer), may not be yet practically 
feasible since UV radiations do not penetrate the skin very 
deeply. Hence, should our results be validated in vivo in 
recognized animal models, we believe that the application 
of molecule-internalizing vectors as those herein and 
others described in the literature [36, 74] to enhance 
permeation of GPCR targeting-drugs through cancer 
cells (if needed) should be actively pursued in therapeutic 
cancer setting.
In conclusion, our data support the existence of an 
intracrine signaling pathway via internal/nuclear B2R that 
appears critical for growth of TNBC cells. We engineered 
new approaches and discovered new tools to target 
intracellular B2R relevant for TNBC. Thus, our research 
has resulted in defining a new class of B2RAs to overcome 
the limited efficacy of current strategies in tackling TNBC. 
In sum, the results highlight the need to target a given 
GPCR in relation to its subcellular localization in order to 
achieve therapeutic outcomes. 
MATERIALS AND METHODS 
Human tissue samples and electron 
immunohistochemistry of B2R
Human triple-negative invasive ductal carcinoma 
(IDC) samples and matched normal adjacent tissue 
specimens were obtained from two patients who 
underwent surgical resection of their primary tumor at the 
Hôtel-Dieu Hospital in Sherbrooke (Québec, Canada). The 
use of the tissue samples was approved by the Institutional 
Review Board. Post-embedding immunogold labeling of 
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B2R was performed on ultrathin Epon sections (50 nm) 
mounted on nickel grids as described [33, 77]. Sections 
were incubated with the rabbit anti-rat (cross-reacting 
to human) B2R antiserum AS-276–83 (1:25) followed 
by incubation with a goat anti-rabbit gold (10 nm)-
conjugated IgG (1:20) (Sigma Chemical Co.). Sections 
were contrasted, embedded and viewed as described [77]. 
Negative controls were carried out by omitting primary 
antibodies, replacing it with preimmune serum or an 
isotype control IgG. The areas of nuclear and cytoplasmic 
portions were measured by using Image J software 
(National Institute of Health, JAVA 1.60_02) [78]. An 
average of 10 to 15 cells covering an area of at least 200 
µm2 per case were examined, and each case generated 
about 50 images of magnifications ranging from 40,000x 
to 60,000x. A total area of 1,904 µm2 was examined in 
normal or cancer cells. Parameters used for statistical 
comparisons were 1) the number of gold particles in the 
nucleus/ nucleus area and 4) the number of gold particles 
in the cytoplasm/ cytoplasmic area. 
Solid phase peptide synthesis
All peptides were assembled on solid support by 
an automated Pioneer peptide synthesizer using Fmoc 
(9-fluorenylmethyoxy-carbonyl) chemistry [34]. Peptides 
were purified by analytical RP-HPLC and were  > 95% 
pure, with expected mass spectra (see supplementary 
Methods Supplementary Figure 4 for details on purification 
and identification of peptides used in this study). As part 
of a project that aimed to design new cell-penetrating 
peptides, we synthesized a series of cell-penetrating 
kinin peptides by linking the modified HIV-1 Tat peptide 
sequence H-48GRKKRRQRRR58-OH in d-configuration 
(to confer proteolytic stability) to the N-side of BK and 
HOE 140 sequence terminated with 3 glycyl residues as 
a spacer (for steric hindrance considerations). Another 
approach consisted of conjugating the steroidal moiety 
cholic acid to the N-terminal part of the peptide HOE 140 
linked to the resin. Fluorescein isothiocyanate (FITC) was 
linked to a β-alanine residue added to the N-teminus of 
the peptide HOE 140 and dTat-HOE 140 still attached to 
the resin. Peptides were stored in powder form at – 20°C. 
Stock solutions (10 mM) of peptides were also prepared in 
Nanopure water, except for the steroid peptide conjugate, 
which was prepared in 50% ethanol-50% Nanopure water, 
and then stored at – 20°C until use. The non-peptide B2R 
antagonist FR173657 was provided by Astellas Pharma 
Inc. (formelly Fujisawa Pharmaceutical Co, Japan) [79] 
and was prepared in 50% dimethyl sulfoxide (DMSO)-
50% Nanopure water.
Distribution coefficient of compounds
The distribution coefficient of compounds (log D) 
between n-octanol and 0.1 M sodium phosphate buffer, 
pH 7.4, was determined by the classical shake flask 
methodology; this parameter is thought to be a good 
predictor of the cell membrane permeability. Equal 
volumes of octanol and PBS (137 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4), were mixed 
and allowed to equilibrate for 24h. The layers were then 
separated and stored at 4°C. At testing, the compounds 
(200 µM) was added to 200 µl of aqueous phase and 
mixed with an equal volume of octanol by vortexing for 
2 min. The octanol/buffer solution was centrifuged for 5 
min at 1000 x g. After separation into aqueous and octanol 
phases, compound content of the aqueous and octanol 
phases was quantified by RP-HPLC (Agilent1100 series). 
Partition coefficients of compounds were expressed as the 
ratio of peptide found in the octanol phase to that found 
in the aqueous phase. All octanol/buffer distribution 
studies were performed in duplicate. The octanol/buffer 
coefficient was calculated as the ratio of octanol layer to 
the buffer layer. Compounds with log D values higher than 
0 and less than 3 fall into the highly permeable class.
Binding assays
Radioligand competition binding assays were 
performed on live adherent HEK-293T cells transiently 
transfected with human B2R using [3H]LysdesArg9-
BK, according to Bélanger et al [34]. Binding affinity 
of the compounds is expressed in terms of IC50 value: 
the molar concentration of an unlabeled agonist causing 
50% displacement of specific binding. Radioligand 
competition binding assays was also conducted on 
MDA-MB-231 nuclear extracts using 125I-hpp-HOE 140 
prepared as described previously [80]. Briefly, binding 
assays was done in presence of 0.5 nM 125I-hpp-HOE 
140 with or without 1 µM HOE 140 (B2R selective) or 
1 µM R954 (B1R selective) in a buffer solution of 50 
mM Tris-HCl, pH 7.4, 10 mM MgCl2, 10 µM captopril 
and 10 µM thiorphan. Reaction was initiated by adding 
200 µg of nuclear protein extracts and the incubation 
conducted at room temperature for 1h. Each measurement 
was performed in triplicate in a final assay volume of 
100 µl. This incubation was terminated by rapid filtration 
through GF/C filters (Whatman) soaked in 0.3% (vol/
vol) polyethyleimine/binding buffer. Cell nuclear bound 
radioactivity was measured using a γ-radiation counter 
(WIZARD2, Perkin Elmer).
Functional bioassays with isolated human vessels
For testing the pharmacological activities of 
agonists, complete concentration-contractile response 
curves to agents were done at the B2R endogenously 
expressed in the human de-endothelized umbilical 
veins (hUV), as previously described [34]. EC50 values 
(or potencies) of the agonists were calculated from the 
obtained concentration-response curves. Antagonist 
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apparent affinity is expressed in term of IC50 value: 
the molar concentration of an antagonist that reduces a 
specified BK submaximal response to 50% of its former 
value. The collection of umbilical cords for the bioassays 
was approved by the local ethical committee, and maternal 
consent was obtained in every case.
Cell culture and reagents
The human breast cancer cell line MDA-MB-231 
and COS-1 monkey kidney epithelial cells were 
maintained in DMEM medium containing 10% heat 
inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 
100 U mL−1 penicillin and 100 µg/mL streptomycin. The 
primary culture of cerebral microvascular endothelial cells 
from piglets (courtesy of Dr. S. Chemtob, Canada) was 
cultured in DMEM medium as described [81, 82]. Cells 
were treated as described in figure legends or specific 
method section.
Antibodies were obtained from the following 
sources: anti-clathrin antibody, anti-Na+/K+ ATPase 
antibody, anti-lamin A/C antibody, anti-Bcl-2 antibody, 
anti-cyclin A antibody, anti-p27 antibody (Santa Cruz 
Biotechnology); anti-β-actin antibody (Sigma-Aldrich); 
anti-MAPK p42/p44 antibody (Promega); anti-XIAP 
antibody (Stressgen); anti-calnexin antibody, anti-Ki67 
antibody (Abcam); anti-Akt antibody (New England 
BioLabs); anti-p38 antibody (Chemicon international); anti 
phospho-p38 antibody (Millipore); anti-hB2R antibody 
(C-terminus) (LS-A797: LifeSpan Biosciences); anti-
LAMP-2 antibody (ALZForum); anti-GBM-130 antibody 
(BD Transduction Laboratories); anti-Bad antibody (BD 
Biosciences); rabbit polyclonal Isotype control antibody 
(Dako). The rabbit anti-human B2R antisera AS276–83 
(targeting 8 distinct epitopes on the extra–and intracellular 
domains of B2R) and the mouse monoclonal antibody 
anti-human kininogens (directed to domain D1) were 
provided by Pr W. Muller-Esterl (University Frankfurt) 
whereas the rabbit polyclonal anti-tissue kallikreins and 
anti-BK antisera were provided by Prs F Alhenc-Gelas 
and N Bouby (INSERM). Chemotherapeutic agents 
were obtained from the following suppliers: carmustine 
(or BCNU) and paclitaxel (Taxol) (Sigma-Aldrich); 
doxorubicin (Adriamycin), carboplatin (Paraplatin), 
temozolomide (Temodar) (pharmacy department of the 
Centre Hospitalier Universitaire de Sherbrooke (CHUS)).
Generation of lentiviruses and infection
Custom non-target (scrambled control) 
and human B2R targeting lentiviral short hairpin 
RNA (shRNA) expression-pLKO.1 vectors were 
purchased from Sigma-Aldrich. The non-targeted 
and targeted sequences were as follows: shRNA 
scrambled: 5′CCTAAGGTTAAGTCGCCCTCG 
CTCGAGC GAGGGCGACTTAACCTTAGG3′ (Addgene 
plasmid # 1864) shRNA-B2R: 5′CCGGCGAGCGCATC 
ATCGATGTAATCTCGAGATTACATCGATGATGCGC 
TCGTTTTT3′ (designated as shRNA-1). The shRNA 
lentiviruses production in HEK-293T cells and the 
infection of MDA-MB-231 cells with the viral suspension 
were performed according to manufacturer’s instructions 
(Sigma-Aldrich). MDA-MB-231 cells stably infected with 
lentiviruses encoding shRNA-B2R or scrambled shRNA 
sequence were obtained after a 10 day selection with 
puromycin (2 μg/mL).
Real-time quantitative RT-PCR
Total cell RNA was isolated with the RNeasy 
mini kit (Qiagen, Toronto, ON, Canada) according 
to the manufacturer’s protocol. Reverse transcription 
was performed at 42°C for 50 min, using SuperScript 
II reverse transcriptase and random hexamer primers 
(Invitrogen). Quantitative PCR was performed on an 
M3000p Stratagene instrument (Agilent technologies), 
40 cycles of 95°C for 15s and 60°C for 30s using 
SYBR Green (Quanta Biosciences). The following 
primers were used: for B2R (NM_000623.3), 
5′-AGTACCAGGGAGCGACTGAA-3′ (forward) 
and 5′-GTGACATTGAGCATGTCGGC-3′ (reverse) 
(amplicon length, 176 bp); for β-actin (NM_001101.3), 
5′-GTTGCTATCCAGGCTGTGCTA-3′ (forward) 
and 5′-GCGGATGTCCACGTCACACTT-3′ (reverse) 
(amplicon length, 471 bp). The comparative Ct method 
was used to quantify transcripts that were normalized 
with respect to β-actin expression. Control reactions 
were performed in the absence of reverse transcriptase 
to demonstrate that residual contaminating DNA is not 
present in our RNA preparation.
Clonogenic assay
MDA-MB-231 cells were plated at 200 cells/well in 
a six-well dish in 2 ml DMEM medium containing 10% 
FBS. For establishing concentration-response curves, cells 
were treated with either B2R agonists (BK and dTat-BK) 
or antagonists (HOE 140, dTat-HOE 140 (NG68), Cholic-
HOE 140 (NG134) or FR173657) at concentrations 
ranging from 1 to 100 µM. In some experiments, cells 
were pre-exposed to HOE 140 10 µM (for obstructing 
cell-surface B2R) for 15 min, and then incubated with 
the other tested B2R antagonists (NG68, NG134 or 
FR173657). After 10 to 14 days, colonies were fixed and 
stained with 0.5% methylene blue in 50% ethanol. Excess 
of staining solution was removed carefully with tap water 
and the plates were dried overnight. Colony counting and 
densitometric analyses (to measure total colony numbers 
and surface areas) were performed using the Image Pro 
Plus 5.1 software. 
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Anchorage-independent growth (soft agar assay) 
MDA-MB-231 cells were seeded out into 6-well 
plates (at 6,000 cells per well) and cultured in DMEM 
media with 10% FBS. The following day, cells were 
treated with and without the B2RAs at the indicated 
concentrations for one week. At the end of treatment, 
about 3,000 viable cells were resuspended in 3 mL of 
DMEM medium containing 10% FBS. Molten agar 
(about 42°C) was added to each tube containing the cell 
suspension, and the agar-cell mixture was promptly put 
into wells of a 6-well plate. To avoid drying of agar, 1 
mL of DMEM (10% FBS) was added to each well, and 
renewed every few days. Cells were incubated at 37°C 
for about 3 weeks. Colonies were counted by two persons 
blindly (AF, VB) without any form of staining using an 
inverted microscope.
Cellular fractionation 
Cell fractionation and nuclei isolation were 
achieved by the hypotonic/Nonidet P-40 lysis methods 
[82] with slight modifications. Briefly, cells were 
harvested at confluency, washed in pre-warmed HBSS 
then resuspended in hypotonic cell lysis buffer (20 
mM Tris-HCl pH 7.2, 10 mM KCl, 3 mM MgCl2, with 
protease inhibitors). Cell were left to swell on ice for 
an hour and then lysed in presence of NP40 (0.1% vol/
vol) using a Dounce homogenizer (300 strokes, tight 
pestle). Nuclei were washed twice (7 min at 800g, 4oC) 
in lysis buffer and nuclei purity was verified under phase 
contrast microscope. The supernatant from the first 
centrifugation of cell lysates was sequentially centrifuged 
at 10,000g, 4ºC for 15 min (to pellet mitochondria), and 
then at 200,000 g, 4ºC for 60 min (to pellet membranes). 
Membranes were resuspended in Phosphate buffer 
containing protease inhibitors. Total proteins in cell 
lysates, nuclear and membrane suspensions were 
measured using BCA™ (bicinchoninic acid) protein 
assay kit (Pierce).
Western blot analysis
For western blot analysis, appropriate amount of 
cell lysates or membrane and nuclear fractions (25–50 µg 
protein) were denatured, resolved on 9–12% SDS–PAGE 
and electrotransferred onto PVDF membranes. Blots 
were blocked using 5% nonfat dry milk and probed 
using appropriate primary antibodies in blocking buffer 
overnight at 4°C. Proteins were visualized using a goat 
anti-rabbit (1:10 000) or anti-mouse (1:20 000) secondary 
antibody conjugated to HRP and a western lightning 
chemiluminescence detection kit, as per manufacturer’s 
instructions (Perkin Elmer), and revealed by use of Kodak 
X-Omat film. 
MTT proliferation and cytotoxicity assays 
Cell proliferation assay on MDA-MB-231 cells 
was determined with colorimetric MTT as we described 
[9]. Briefly, cells were seeded in a 96 wells plate at 2,000 
cells/well in DMEM media supplemented with 10% FBS 
for 24h at 37°C. Cells were then incubated with and 
without the B2RAs at the indicated concentrations for the 
time shown. At the end of treatment period, MTT (0.25 
mg/ml) was added to the cells and incubated for 1h30 
at 37°C. Thereafter, the cell medium was removed, the 
formazan product solubilized in acidified isopropanol 
(100 µl of 1N HCl/anhydrous isopropanol 1:25) and 
the absorbance determined at 570 nm with an ELISA 
microplate reader (Spectra Max Plus, Molecular Devices, 
Sunnyvale, CA). For assessing the cytotoxicity of B2RAs 
and chemotherapeutic agents (carmustine, doxorubicin, 
carboplatin, temozolomide and paclitaxel) [83], cells were 
grown to confluency in multi-well plates and exposed to 
starving media (DMEM without FBS) for 24h before 
beginning of the antagonist treatment. Cells were then 
incubated with MTT and treated exactly as described 
above. Cell viability was expressed as a percentage of 
optical density (OD) values obtained upon treatment 
relative to control. 
Senescence
The effect of B2RAs on cellular senescence was 
assessed using the Senescence β-Galactosidase Staining 
Kit (Cell Signaling). MDA-MB-231 cells were plated at 
500 000 cells/well in 6-well plates, and serum-starved right 
before the beginning of treatments. Cells were treated with 
and without the B2RAs at the indicated concentrations for 
72 h. At the end of treatment, surviving cells were fixed 
with 2% formaldehyde, 0.2% glutaraldehyde for 15 min 
at room temperature. Fixed cells were then washed and 
stained with fresh senescence-associated β-galactosidase 
stain solution (sodium phosphate buffer, pH 6.0, 
containing 1mg of X-gal (5-bromo-4-chloro-3-indolyl-β-d-
galactopyranoside)/ml 40 mM citric acid, 5 mM potassium 
ferrocyanide, 5 mM potassium ferricyanide, 150 mM 
NaCl, 2 mM MgCl2) at 37°C. Staining was detected by 
light microscopy. As a positive control for senescence, we 
serum starved porcine cerebral microvascular endothelial 
cells (pCMVEC) (kindly provided by S Chemtob) for 48 h.
Flow cytometry 
The subcellular distribution of B2R in MDA-MB-231 
cells was determined by flow cytometry (FACS) analysis. 
MDA-MB-231 cells were detached from culture flasks 
by accutase treatment, washed in blocking buffer (PBS 
and 0.5% BSA) with or without 0.1% saponin (for cell 
permeabilization), and then incubated with the anti-B2R 
antibody LS-A797 or AS276–83 (1:500) for 60 minutes at 
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4°C under mild agitation. Thereafter, cells were centrifuged, 
resuspended in the same blocking buffer (+/- 0.1% saponin) 
and incubated with the Alexa Fluor 488 goat anti-rabbit IgG 
antibody conjugate (1:300) under the same condition as 
set out above. Negative controls included the omission of 
the primary antibody. A similar protocol was used for B2R 
staining of isolated nuclei from the same cells. Samples 
containing cells (or nuclei alone) in suspension were 
analyzed by flow cytometry (FACScan, BD Biosciences) 
equipped with a Cell Quest software (BD Biosciences).
Annexin-V- Propidium iodide (PI) staining 
(apoptosis)
MDA-MB-231 and COS-1 cells were plated at 
500,000/well in 6-well plates containing medium (10% 
FBS/DMEM), and allowed to adhere for about 18 h. On 
the next day, cells were serum-starved and then treated with 
and without the B2RAs at the indicated concentrations for 
24 h. To assess induction of apoptosis due to treatment, we 
used the Annexin-V-FLUOS Staining kit (Roche) according 
to manufacturer’s specifications. Briefly, at the end of 
treatments, cells were harvested, rinsed and incubated in 
100 µl of Annexin-V-FLUOS labeling solution (containing 
2 µl of Annexin-V-Fluos reagent and 1 µl of PI (15 µg/ml)) 
for 15 min at room temperature. Cells were analyzed on 
a FACSCanto II flow cytometer (BD Biosciences). Early 
stage apoptosis was measured using annexin V-Fluos 
(RocheMolecular Biochemicals) in conjunction with PI 
(Sigma) to distinguish among early apoptosis and late 
apoptosis/necrosis. Bar diagram showing the distribution 
of early, late/necrotic cell populations. 
PI staining (cell cycle)
MDA-MB-231 were plated at 500,000/plate in 10 cm 
plates containing medium (10% FBS/DMEM), and allowed 
to adhere for about 18 h. Thereafter, cells were serum-
starved and treated with and without the B2RAs at the 
indicated concentrations for 24 h. At the end of treatments, 
cells were harvested, rinsed and fixed with ice cold ethanol 
95%, for 2 h at 4°C. Fixed cells were rehydrated with 800 
µl PBS for 30 min, and then washed again with PBS to 
remove all traces of ethanol. Cells were treated with RNase 
for 30 min prior to staining. PI was added to cell suspension 
at a concentration of 15 µg/ml and incubated overnight at 
4°C. PI staining was assessed by flow cytometry using a 
FACSCanto II flow cytometer (BD Biosciences).
Ki67 staining (proliferation index)
MDA-MB-231 were plated at 1 × 106 cells/plate 
in 10 cm plates containing medium (10% FBS/DMEM). 
48 h after seeding, cells were washed three times with 
Hank’s balanced salt solution (HBSS) then harvested from 
cell culture dishes using Hank’s-based cell dissociation 
buffer (Life Technologies) and further washed with PBS 
(pH 7.4, containing 5% (vol/vol) FBS) by centrifugation. 
The pelleted cells were resuspended by gentle vortexing 
in 70% cold ethanol (added drop-wise) and kept overnight 
at -20°C. The fixed cell suspensions were rinsed with cold 
PBS and permeabilized with 0.1% (wt/vol) saponin/ 5% 
(vol/vol) FBS/ PBS (pH 7.4) for 30 min, and stained with 
an anti-Ki67 antibody (dilution 1/100) for 1 h at 4°C. An 
Alexa Fluor 488-conjugated goat anti-rabbit IgG antibody 
was used as a secondary antibody (dilution 1/300). Ki67-
positive cells were analysed by flow cytometry using 
FACSCanto II/ FACSDiva-Software (BD Biosciences).
Confocal microscopy (immunocytochemistry of 
B2R)
Cells were grown on coverslips and fixed with 4% 
paraformaldehyde for 30 min at room temperature before 
proceeding to immunocytochemistry under permeabilized 
and non-permeabilized conditions (see FACS staining 
protocols described above). Non specific binding was 
blocked with PBS containing 5% goat serum and 5% fetal 
calf serum for 45 min at room temperature. Cells were 
then incubated with  AS276-83 (2.5 µg/ml) followed 
by an incubation with a goat anti-rabbit fluorescein 
isothiocyanate (FITC)-conjugated IgG (2 µg/ml) (Santa 
Cruz Biotechnology). To visualize nuclei, the sections 
were counterstained with Hoechst 33258 (Molecular 
Probes). Coverslips were then mounted onto glass slides 
using FluoroGuard TM antifade reagent (Bio-Rad) and 
analyzed with a Multi Probe 2001 confocal argon laser-
scanning system (Molecular Dynamics). Samples were 
imaged using a 60× differential interference contrast oil 
immersion objective lens on a Nikon TE300 microscope 
with a Bio-Rad Radiance 2000 confocal accessory. 
Images were collected by using the same Z values and 
were merged using a Silicon graphic software. Control 
experiments omitting the primary antibody displayed no 
staining (data not shown).
Cellular permeability of B2RAs
Permeability of MDA-MB-231 cells to B2RAs 
was evaluated by either confocal microscopy or LC-MS/
MS analyses. Confocal microscopy. MDA-MB-231 cells 
were grown to 70% confluence on round coverslips in 
6 well plates containing medium (10% FBS/DMEM). 
Cells were then exposed to FITC-HOE 140 (10 µM) or 
FITC-dTat-HOE (10 µM) for 0, 15 and 60 min at 37°C 
in DMEM without FBS. At the end of treatments, cells 
were washed three times with PBS and then fixed with 
4% paraformaldehyde for 30 min at room temperature. 
The presence and localization of the fluorescent staining 
was analyzed by confocal microscopy (FV1000, 
Olympus) coupled to an inverted microscope with a 63× 
oil immersion objective (Olympus). Mass spectrometry. 
Cells at 80% confluence in serum-free DMEM media 
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were treated with a non-toxic concentration (2.5 µM) 
of antagonists at 37°C for the indicated times. At the 
end of treatments, cells underwent an acid wash to 
facilitate the release of surface bound ligands. Cell 
contents were released from hypotonic lysis using a 
40:60 mixture of 15 mM Tris-HCl pH 7.4 / methanol. 
Cell lysates were next sonicated and subjected to protein 
precipitation following addition of 0.1% v/v formic acid. 
Precipitated proteins were removed by centrifugation 
and supernatants were concentrated using a Speedvac 
centrifugal evaporator. The sample was subjected to 
quantification using LC-MS/MS on a triple quadrupole 
mass spectrometer (Agilent G6410B). A calibration 
curve made from nine different concentrations of the 
reference compounds dissolved in suitable HPLC 
mobile phase solvents, was used to estimate antagonist 
intracellular content in each sample. The limit of 
quantification was 75 fmol (1 nM/75 µl).
Drug-drug synergy experiments 
Interactions (synergy, additive, antagonistic 
activities) between CP-B2RAs (FR173657 and NG68) 
and chemotherapeutic drugs (doxorubicin and paclitaxel) 
were evaluated using MTT standard assays. Twenty-
four hours after seeding, cells were treated with CP-
B2RAs, the other testing drug, or in combination. For 
combination testing, CP-B2RAs or the other testing drugs 
were added to plate in triplicate wells in ratios of IC25 
(IC25A: IC25B), and cells are incubated in drug-treated 
medium for 72h and cell viability determined by MTT. 
Synergy was determined by calculating combination 
index (CI) value with the formula CI =  (CA,X / ICx,A) + 
(CB,X / ICx,B), where CA,X and CB,X are concentrations of 
drug A and drug B used in combination to achieve x% 
drug effect. ICx,A and ICx,B are concentrations for single 
agents to achieve the same effect. A CI of less than, equal 
to, and more than 1 indicates synergy, additivity, and 
antagonism, respectively.
Statistics 
Data are presented as mean ± SEM. Statistical 
analyses were performed using either an unpaired 
Student’s t-test or a one-way ANOVA with a Dunnett 
post-hoc test, where appropriate. p values of  <  0.05 were 
considered as significant. 
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